Interest in the antithrombotic potential of diets enriched with fish oil-derived polyunsaturated fatty acids (o-3 PUFAs) prompted us to examine how these fatty acids, when taken preoperatively, affect hemostasis, plasma lipid levels, and production of prostacyclin (PGI2) 6-keto-PGFla, was also increased. Despite changes in platelet function, bleeding time, and vascular PGI2, the perioperative blood loss was not increased in subjects receiving fish oil supplements. Thus, co-3 PUFAs at moderate dosages may exert antithrombotic effects by increasing prostacyclin production by vessel walls as well as by direct inhibition of platelet activity. (Circulation 1990;82:428-438) D e ietary supplementation with fish oil, a source of highly polyunsaturated co -3 fatty acids (w -3 PUFAs), has been proposed as an antithrombotic and antiatherosclerotic therapy.' In healthy subjects, ingestion of fish oils or of purified eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the major polyunsaturated fatty acids in oils from cold-water fish, has been demonstrated to diminish platelet aggregation and to lengthen bleed-
Interest in the antithrombotic potential of diets enriched with fish oil-derived polyunsaturated fatty acids (o-3 PUFAs) prompted us to examine how these fatty acids, when taken preoperatively, affect hemostasis, plasma lipid levels, and production of prostacyclin (PGI2) by vascular tissues in atherosclerotic patients undergoing coronary artery bypass graft surgery. Fifteen patients with angiographically proven coronary artery disease received 3 g/day eicosapentaenoic acid and 1.3 g/day docosahexaenoic acid as capsules of purified fish oil for 28 days before surgery. Platelet aggregation induced by low concentrations of ADP, collagen, and epinephrine decreased (p<0.05) and serum thromboxane B2 decreased 36% (p<0.01) from baseline values. Bleeding times increased 40% (p <0.01) from baseline. Serum triglycerides decreased 50%o (p<0.05) without a change in total serum cholesterol. Spontaneous production of PGI2 measured as 6-ketoprostaglandin F1, (6-keto-PGF1,), its stable hydrolytic product, by saphenous vein and aortic and atrial tissues obtained at surgery was greater in tissues from patients receiving o-3 PUFA supplements than in tissues from matched controls (13.8±2.2 versus 8.6, 21 .0±3.1 versus 11.5±2.1, and 166±13 versus 102±15 ng/g, respectively, all p<0.05). Arachidonate-stimulated production of PGI2, as indicated by increased levels of 6-keto-PGFla, was also increased. Despite changes in platelet function, bleeding time, and vascular PGI2, the perioperative blood loss was not increased in subjects receiving fish oil supplements. Thus, co-3 PUFAs at moderate dosages may exert antithrombotic effects by increasing prostacyclin production by vessel walls as well as by direct inhibition of platelet activity. (Circulation 1990; 82:428-438) D e ietary supplementation with fish oil, a source of highly polyunsaturated co -3 fatty acids (w -3 PUFAs), has been proposed as an antithrombotic and antiatherosclerotic therapy.' In healthy subjects, ingestion of fish oils or of purified eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the major polyunsaturated fatty acids in oils from cold-water fish, has been demonstrated to diminish platelet aggregation and to lengthen bleed-ing time2-4 as well as to decrease plasma triglyceride levels.5-9 Supplementation with fish oil also has an anti-inflammatory effect that results from a decrease in leukocyte function.10-12 These potentially therapeutic effects of w -3 PUFAs are thought to represent See p 639 alterations in the types and amounts of eicosanoid products of o-6 PUFAs ordinarily synthesized by mammalian tissues.13-15 Perioperative administration of fish oil to dogs also prevents proliferation of vascular intimal cells and improves graft patency after vascular graft procedures. '6 Similarly, a recent clinical study indicated that ingestion of fish oil by humans before and after coronary angioplasty was associated with a decreased rate of arterial restenosis.17 Because published reports mainly document a modest, though statistically significant, impairment in platelet function after dietary supplementation with even large amounts of fish oil (50 ml cod liver oil or more than 10 g EPA daily),18 '19 we hypothesized that direct effects on blood vessels might also contribute to the antithrombotic or antiatherosclerotic potency of w-3 PUFAs. To study whether a moderate dosage of fish oil might have both vascular and platelet effects in patients with preexisting atherosclerosis and to determine whether such therapy would be tolerated in patients undergoing surgery without inducing excessive bleeding, we chose to study a series of subjects with proven coronary artery disease who were scheduled for elective coronary artery bypass graft surgery. These subjects received fish oil capsules containing a total of 4.3 g/day of combined EPA and DHA for at least 28 days before surgery. Their plasma lipids, platelet function, and hemostatic function were tested, and the capacity of their blood vessels, obtained at surgery, to produce the antithrombotic substance prostacyclin (PGI2) was measured. The results obtained indicate that potentially antithrombotic vascular effects, as well as changes in plasma lipids, result from moderate fish oil intake and may well augment concomitant antiplatelet effects in contributing to better vascular patency.
Methods

Patient Selection and Study Design
Fifteen patients scheduled for elective coronary artery bypass graft surgery at the Pisa University Hospital, Pisa, Italy, were the subjects of this study. Selection criteria included a negative history of hemostatic disorders; no treatment with anti-inflammatory, antiplatelet, or anticoagulant drugs during the 2 weeks before recruitment; and scheduling for elective bypass surgery alone without additional surgical procedures. Table 1 ).
The two groups studied were well balanced for age, cardiovascular risk factors, preoperative treatment, and hematologic parameters such as blood counts, platelet counts, prothrombin time, and activated partial thromboplastin times (Tables 1 and 2 (Table 2) .
Patients assigned to EPA supplementation were prescribed 10 capsules daily, taken with meals in three doses of three, three, and four capsules each. Customary diets were not otherwise altered. The daily total dose was 3 g EPA and 1.3 g DHA. Patients were given the capsules after they had completed a series of baseline blood tests (described below) and were instructed to keep in touch with the organizing center in case of any intercurrent health problem or need for additional medication. Compliance, as assessed by pill count, was more than 95%. All patients completed a minimum of 28 days of fish oil supplementation, at the end of which the same series of blood tests was repeated and the patients were admitted to the Division of Cardiac Surgery for their operation within the next 7 days. Patients continued to receive fish oil supplementation until the night before surgery. All patients completed the protocol, and all except one, whose clinical condition was reevaluated at the time of hospital admission and deemed not to mandate surgery, underwent the bypass graft procedure. Subjects served as their own controls (before and after fish oil supplementation) for laboratory examinations of blood and platelets. For analysis of vascular fragments and blood loss with surgery, the patient and control groups were compared.
Laboratory Testing
The following tests were performed at baseline (pretreatment) and after 28 days of EPA supplementation.
Platelet adhesiveness was performed by the method of Hellem using disposable glass bead columns (Adeplat, Mascia Brunelli, Milan, Italy) and a constant flow pump (Adeplat) as previously described. 20 Platelet aggregation was carried out on citrated platelet-rich plasma, using a Payton dual-channel aggregation module equipped with a Rijken Denshi recorder (Buffalo, N.Y.), with additions to platelet samples of the following fixed final concentrations of aggregating agents: ADP (Stago, Asnieres, France), 1 and 2.5 ,uM; epinephrine (Stago), 0.75 and 2.5 ,uM; arachidonic acid (BioData, Hatboro, Pa.), 1 mM; collagen (Mascia Brunelli), 1.5 and 150 mg/ml; platelet aggregating factor (PAF-acether, CalbiochemBehring, La Jolla, Calif.), 1 23 Serum thromboxane B2 (TXB2) was measured in clotted blood prepared by placing duplicate 1-ml samples of freshly drawn, unanticoagulated blood into clean glass tubes that were kept at 370 C for 90 minutes. The serum was then promptly separated by centrifugation and was frozen at -30°C until assay. Serum TXB2 levels were measured by radioimmunoassay.
Vascular Prostacyclin
Measurement of the production of PGI2 by vascular fragments was performed as previously described.24 Briefly, fragments of atrium, aorta, and saphenous vein removed during the course of the coronary artery bypass graft surgery were placed in iced tissue culture medium containing newborn calf serum and papaverine, kept on ice, and processed within 3 hours. The fragments were cut into grossly uniform pieces, gently washed free of blood in three changes of HEPESbuffered saline containing divalent cations (HBS), and weighed in tared tubes. The average wet weight (mean+ SD) was 270+93 mg for atrium, 176±54 mg for saphenous vein, and 66±24 mg for aorta; there was no significant difference between fragments from patients taking co-3 PUFA supplements and those from controls. Duplicate samples were warmed to 370 C and were subjected to sequential 10-minute stimulation at 370 C in 0.5 ml (for aortic fragments) or 1 ml volumes (for all other fragmnents) first in HBS and then in HBS plus 25 ,M arachidonic acid. After each step, the fluid was removed, centrifuged to remove cells, and stored frozen until assay. Saphenous vein samples were also assayed for luminal surface production of PGI2. These samples were opened, inserted flat in an incubation chamber (designed by Dr. Eric Grabowski, Cornell Medical Center, New York) with the endothelial surface facing the chamber lumen, and incubated as above. Preliminary experiments determined that endothelium was preserved during these studies. The production of PGI2 during these incubations was expressed as nanograms per gram of tissue wet weight for incubated fragments and nanograms per centimeter squared for chamber studies. PGI2 production was determined by radioimmunoassay for its stable hydrolytic product 6-keto-prostaglandin F1, using a tritiated tracer (New England Nuclear; specific activity, 120 Cilmmol), authentic standard (kindly provided by Dr. J. Pike, Upjohn Co., Kalamazoo, Mich.), a specific antiserum (gift of Dr. J. Salmon, Wellcome Research Laboratories, Beckenham, UK) at a final dilution of 1:10,000, and separation with dextrancoated charcoal. The sensitivity of this assay was 1.8+0.6 pg/ml, evaluated by a 5% lowering of the binding capacity. In these assay conditions the antiserum used showed a cross-reactivity of 5% with A'7-6-keto-PGF2C, the stable hydrolytic metabolite of PG13.
Assays were performed blinded as to subject treatment.
Unnary Eicosanoid Metabolites
Urine was collected at night from subjects in the treatment group at the time of baseline examination and again on day 28 of fish oil supplementation. Urine was analyzed for the presence and the excretion rate of the main urinary metabolites of plasma TXB2 and PGI2, namely, 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-PGF,,, as well as for the corresponding metabolites of the co -3 series, by negative ion-chemical ionization gas chromatography-mass spectrometry.25,26 Results were expressed in nanograms per milligram creatinine. These analyses were performed in the laboratory of Dr. Garrett A. FitzGerald, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tenn.
Postoperative Bleeding
Postoperative blood loss was evaluated by recording chest tube drainage. In addition, the nadirs of hematocrit and platelet count, the amount and types of transfusion given, and duration of hospitalization were noted.
Statistical Methods
Comparisons of values obtained in the same subjects before and after 28 days of supplementation with fish oil were performed by the paired Student's t test. Comparisons of the two groups of subjects for frequency data were made by the x2 test. All other quantitative data, including prostacyclin production, were evaluated by the Student's t test for unpaired data.
Results
Effects of Dietary Supplementation With Fish Oil on
Serum Lipids
In all patients but one taking fish oil wo-3 PUFAs for 28 days, there was a significant decrease in serum triglyceride levels (Figure 1 ). Those subjects with the highest initial triglyceride levels had the most marked decrease, but levels also decreased in those who had lower initial levels. In those patients also studied after 14 days of -3 PUFA supplements, a significant In contrast, only minimal changes in serum cholesterol were observed during the study period in subjects taking fish oil supplements (Figure 2 ). Total serum cholesterol was unchanged; total HDL cholesterol was slightly but significantly reduced during w -3 PUFA supplementation as the result of small decreases in both HDL2 and HDL3 (Figure 3) .
Incorporation of w-3 Fatty Acids Into Platelet Lipids
Dietary supplementation with fish oil resulted in increased levels of wo-3 fatty acids in total platelet lipids after 2 as well as after 4 weeks of treatment ( Figure 4 ). These increases involved each type of w -3 fatty acid measured from 18: 3 w -3 through 22: 6 w-3 (data not shown). Decreases ( Table 3 ). At 14 days of treatment, however, aggregation responses were similar to baseline values despite evidence of incorporation of co -3 fatty acids into the platelet lipids (data not shown). Platelet aggregation responses to strong stimuli that activate platelets by means independent of the production of arachidonic acid metabolites were unchanged by dietary supplementation with co-3 PUFAs.
Serum TXB2 was consistently reduced in all subjects by dietary supplementation with fish oil ( Figure  5 ). Although the serum TXB2 levels of the two subjects with the highest initial values had decreased by nearly 50% by day 28, we observed no consistent correlation between initial levels of serum TXB2 and the decrease during therapy. Baseline bleeding times in the patients who received fish oil dietary supplementation ranged from 4.4 to 8.5 minutes (mean, 6.0+±1.5 minutes). After 14 days of treatment, there was no significant change from baseline (data not shown), but after 28 days a significant increase in bleeding time was observed in 11 of 15 patients ( Figure 6 ). In four subjects, the bleeding time increased to more than 10 minutes. There was no correlation between the baseline bleeding time and the extent of change after dietary supplementation. Correlation with platelet aggregation studies and serum TXB2 levels, as well as direct questioning of subjects, indicated that no subject had taken aspirin (another nonsteroidal anti-inflammatory drug) or any other antiplatelet medication that might have contributed to a prolonged bleeding time during the period of dietary supplementation.
Despite the increase in bleeding time during the period of dietary supplementation with fish oil, the patients so treated did not have significantly increased bleeding at or after surgery compared with matched control patients ( (Figure 7 ). Increased PGI2 production was observed in all tissues examined-atrium, which represents a mainly microvascular source of PGI2, and both aorta and saphenous vein, where PGI2 produced by smooth muscle cells is an important addition to that produced by endothelium. Moreover, production of PGI2 by the endothelial surface of the saphenous vein (measured by an incubation chamber technique that excludes contribution by deeper smooth muscle cells) was also increased, indicating that the cw-3 PUFA supplementation had a stimulatory effect on production of PGI2 by large-vessel endothelium.
Urinary Excretion of Prostacyclin and Thromboxane Metabolites
Measurements of metabolites of PGI2, PGI3, TXA2, and TXA3 in urine collected at the baseline and 28-day time points documented small increases in PGI3 and TXA3 metabolites, with some fall in TXA2 metabolites following treatment. Because of considerable interpatient variation, no significant changes in the urinary metabolites of these eicosanoids were detected.
Discussion
The results of this study indicate that a moderate daily intake of fish oil containing the to-3 PUFAs EPA and DHA by patients with coronary artery disease affects both vascular and platelet function. Enhanced production of PGI2 by vascular tissue, diminished platelet activation, decreased TXA2 formation, and reduced serum triglycerides were observed after 4 weeks of cw-3 PUFA intake. These changes took place without increased perioperative blood loss during the coronary artery bypass surgery carried out at the end of the period of w -3 PUFA administration. Each of the observed effects on the vessel wall, platelets, and serum lipids may contribute to the antithrombotic potential of this dietary intervention. Because PGI2 can inhibit smooth muscle cell proliferation and stimulate cholesteryl ester hydrolysis, its increased production may have an antiatherogenic effect as well.
The dietary supplement altered the relative proportions of w -3 and -6 PUFAs in platelet lipids without affecting the levels of saturated or monounsaturated fatty acids. The observed increase in total cw -3 fatty acids and in each type of PUFA were all significant compared with baseline and were associated with decreased platelet function, although the extent of shifts in fatty acid levels in our study were clearly less than those produced in studies of higher PUFA dosages. '8"19 We also noted a highly significant reduction in plasma triglycerides both in subjects with elevated and those with normal baseline serum triglyceride levels, effects similar to those reported after much larger doses of fish oil or longer treatment periods.19 '27 In contrast, total plasma cholesterol was unchanged, although nonsignificant decreases of HDL cholesterol and corresponding increases of low density lipoprotein (LDL) cholesterol were observed, most likely reflecting the reduction in triglycerides and consequent partial rearrangement of very low density lipoproteins into LDL. While changes in physical activity or diet can be associated with changes in plasma lipids, the subjects were counseled to continue their usual activities and diets during the study period and, as far as could be determined, they complied. Serum triglyceride values in the control subjects were similar to those obtained at baseline in the patients subsequently given fish oil.
In this study, wo -3 PUFA intake was associated with a small decrease in platelet adhesiveness, a decrease in platelet aggregation, and a consistent reduction in the level of TXB2 generated in clotting blood compared with baseline values; this last reflects decreased maximal platelet capacity to produce TXA2. Thus, both threshold and maximal platelet responses were decreased by ingestion of w -3 PUFAs. These effects of fish oil were, however, much weaker than the inhibitory effects of aspirin on platelet function. Even a high dosage of fish oil results in only partial inhibition of platelet function. 18"19 Indeed, it is unlikely that the decrease of thromboxane-generating capacity directly causes the decrease of platelet responses to low concentrations of aggregating agents because only about 5% of normal TXA2 production is needed to support normal platelet aggregation responses,28 whereas approximately 50% of baseline levels of TXB2 was produced by the platelets of our w -3 PUFA-treated subjects. In addition, platelet aggregation responses to arachidonic acid in these subjects were only partially inhibited, another indication that the depression in thromboxane production was modest. In contrast to these results, the bleeding time in the treated patients was prolonged by an average of 40%, an increase most likely independent of decreased TXA2 generation. In previous work, we have demonstrated that a small dose of aspirin, for example, 20 mg/day, could selectively block platelet TXA2 synthesis by more than 95% without prolonging the bleeding time.28 These results, taken together, suggest that co -3 PUFA ingestion has actions on the vessel wall, in addition to effects on platelets, that affect bleeding time.
The capacity of the vascular tissues to produce PG12 either spontaneously or upon stimulation was greater in subjects receiving fish oil co -3 PUFAs than in a control group of clinically similar subjects who did not receive co-3 PUFAs. The method by which total prostacyclins were measured in these studies underestimated the amount of PGL1 present; based on the tissue lipid results, it probably also increased from initial levels. We observed elevated PGI2 levels in all vascular tissues examined from w-3 PUFA-treated subjects, including arterial and venous large vessels (aorta and saphenous vein) and microvessels (atrium). In our experience, aortic fragments from these patients are almost always affected by atherosclerosis,24'28 whereas the saphenous veins and atria are not, suggesting that both atherosclerotic and normal tissues can exhibit altered prostaglandin production in response to cw -3 PUFAs. PGI2 produced by the endothelial surface of the saphenous veins from co -3 PUFAtreated subjects (under conditions that prevented cut surfaces or deeper vascular layers from contributing PGI2) was also increased, indicating that increased PGL2 was produced at the vascular surface that contacts the blood, where maximum effects on hemostasis occur. PUFA, polyunsaturated fatty acids; WB, whole blood; RBC, erythrocytes.
Interpretation of the increased production of PGI2 by vascular tissues from subjects receiving the wo-3 PUFA supplements is tempered by the fact that this study did not include a placebo-treated control group; it is conceivable that subtle differences in the case control population in activities, diet, or medication might have contributed to the observed results.
As far as could be determined, however, the control subjects were well matched for age, extent of diseases, risk factors, activities, and other treatment, and a single surgeon performed all of the operative procedures. We hope that such a controlled trial to confirm these findings will soon be feasible.
Urinary excretion of prostacyclin and thromboxane metabolites did not change significantly from baseline levels in the subjects receiving co-3 PUFA supplements for the 28-day study period, although a trend toward increased excretion of TXA3 metabolites was observed. These urinary measurements reflect actual time-integrated excretion of eicosanoids rather than total synthetic capacity during stimulation (as we measured in the studies of vascular fragments). Previous studies of prostanoid excretion in normal18 and in atherosclerotic19 subjects have suggested that a higher dosage of fish oil (10 g/day EPA) is necessary before consistent increases in urinary ws-3 eicosanoid metabolites can be detected, even by the very sensitive technique of selective negative ion-chemical ionization gas chromatography-mass spectrometry. Moreover, urinary PGI2 metabolites reflect the balance between intrinsic vascular synthesis and platelet-vessel wall interactions. In normal subjects, no change in PGI2 metabolites has been observed, whereas the net sum of PGI1 and PGI1 metabolites is increased.18 By contrast, in patients with severe peripheral vascular disease a net decrease in PGI2 metabolites followed cw -3 PUFA administration, largely as a consequence of treatment-induced decreases in platelet-vessel wall interactions that had caused elevated PGI2 formation and excretion at baseline testing. 29 In addition, levels of thromboxane metabolites elevated at baseline have been reported to fall during fish oil administration.27,30 Our subjects did not have overt peripheral vascular disease, had normal circulating platelet aggregate ratios, and demonstrated relatively normal excretion of PGI2 and TXA2 metabolites at baseline, all indications that they did not manifest a generalized increase in platelet activation in vivo or increased platelet-vessel wall interaction. Our results clearly demonstrate that o -3 PUFAs enhance vascular prostacyclin production capacity in different types of blood vessels independent of platelet-vessel wall interactions. Our findings also suggest that such increased production capacity for prostacyclins occurs both in atherosclerotic and normal vascular tissues.
Hemostatic modifications induced by Co-3 PUFA supplementation are complex and must represent more than a simple shift from platelet synthesis of bioactive TXA2 to inactive TXA3. Our data on bleeding time prolongation point to effects of co-3 PUFAs on the vessel wall or on platelet interactions with the vessel wall. It is also likely that C-3 PUFA treatment increases the release of endothelial cell relaxing factor, by the vessel wall, as shown in animals.31 Such an effect, not directly tested in this study, would be expected to augment the effects of PGI2 on platelet function and bleeding time. The precise mechanisms by which C-3 PUFAs exert an antithrombotic effect may be more directly addressed by our ex vivo system in which access to fresh human vascular tissue is possible.
Our study also provides evidence for the safety of administering fish oil at a dose that affects both platelet and vascular wall function, in the setting of vascular surgery, where the goal is to avoid thrombosis without inducing a bleeding tendency. For example, a recent study of the effects of aspirin and dipyridamole on the outcome of coronary artery bypass grafts demonstrated that subjects treated preoperatively with these antiplatelet drugs had significantly more intraoperative and postoperative bleeding.32 While aspirin dosage in excess of that needed to provide antiplatelet effects probably accounted for these results, this study suggests that alternative therapies would be useful in a surgical setting.
Perioperative ingestion of fish oil has resulted in improved patency and decreased intimal proliferation of experimental vascular grafts in dogs.16 w-3 PUFA administration before coronary angioplasty was associated with decreased restenosis rates in human subjects in one study,17 although such a benefit has not been documented in other, larger clinical trials33,34 in which preangioplasty treatment with o -3 PUFAs has been brief. The findings in the present study and others18 suggest that full platelet and perhaps vascular effects of w-3 PUFAs may take 1-2 weeks to develop. Increasing evidence indicates that several different mechanisms might underlie a beneficial effect. Abnormal coronary artery vasoconstrictor responses also improved after fish oil supplementation. 35 Addition of co5-3 PUFAs to bovine endothelial cells in tissue culture decreased the release of growth factors from the cells. 36 In vitro, co-3 PUFAs also decreased release of growth factors from monocytes.37 Moreover, fish oil administration to normal human subjects diminished the release from peripheral blood monocytes of inflammatory mediators such as interleukin-1, a stimulus to vascular smooth muscle cell proliferation.12 If fish oil administration similarly affects growth factor release from human tissues, it might indicate that there were an additional, potentially antiatherogenic effect of PUFAs in clinical settings such as angioplasty or coronary artery bypass graft surgery.
The results of our present study, in which dosage of Go-3 PUFAs similar to that which reduced restenosis after angioplasty17 and diminished monocyte release of cytokines12 was administered to patients scheduled for coronary artery bypass graft surgery, suggest that extraplatelet effects of Co -3 PUFAs, such as enhancement of vascular prostacyclin production contribute to the antithrombotic effects and potentially to other antiatherosclerotic actions. Our findings also indicate the hemostatic safety of preoperatively administering wo-3 PUFAs in a surgical setting and suggest that moderate doses of wto-3 PUFAs have potentially beneficial effects on vascular physiology, platelet reactivity, and plasma lipid status that may combine to improve outcome in revascularization procedures.
